Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

Eli Lilly and Company -0.41% Pre

Eli Lilly and Company

LLY

1003.57

1005.90

-0.41%

+0.23% Pre

- Novo Nordisk NOVOb.CO said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s Tirzepatide in reducing body weight.


Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via